OpenResearchAlpha

bioRxiv · 20 Nov 2026

TEAD Palmitoylation Inhibitors are Brain Penetrant and Enhance Survival in Preclinical Models of Recurrent Glioblastoma in Combination with Standard-of-Care Therapy

Thenzing Juda Silva Hurtadoh-index 2, Balagopal Pai, Mohammad Imran K. Khan, Debdatta Halder, Anne Marie Barrette, Timothy E Richardson, Anirudh Sattiraju, Roland H Friedel, Hongyan Zou, Dolores Hambardzumyan, Raymund L Young, Tracy T Tang, Nadejda M Tsankova

0
Citations
no database records one yet
0
Citations in 2026
so far
2
Leading author's h-index
Thenzing Juda Silva Hurtado, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Purpose: Oncogenic addiction to YAP-TEAD signaling drives adaptive plasticity, therapeutic resistance, invasion and tumor progression in many cancers, including in glioblastoma (GBM), and represents an actionable vulnerability to explore as adjuvant therapy during tumor recurrence. This study evaluated the translational potential of orally bioavailable Vivace Therapeutics (VT) TEAD palmitoylation inhibitors in preclinical GBM models. Experimental Design: The effects of VT103 and VT104 on GBM proliferation, migration, and TEAD activity were first assessed across patient-derived GBM cell lines with diverse genomic drivers. The drugs pharmacokinetics (PK) and biodistribution were measured using mass spectrometry in mice bearing patient-derived orthotopic xenograft (PDX) GBM. Therapeutic efficacy was evaluated in two genetically distinct PDX models of recurrent GBM, administering VT104 as monotherapy or in combination with standard-of-care radiotherapy plus temozolomide (RT+TMZ). Results: VT104/VT103 treatment significantly impaired GBM proliferation and migration in-vitro, with concomitant downregulation of TEAD-target expression. PK studies confirmed sustained VT104 plasma levels and robust brain biodistribution in PDX mice, with brain:plasma ratio >150% at therapeutic dosing without systemic toxicity. While VT104 monotherapy showed modest anti-tumor effects, combination therapy (VT104+RT+TMZ) significantly extended overall survival in both recurrent GBM PDX models. The survival benefit was most prominent in EGFR-mutant GBM and corresponded to significant decrease in overall and infiltrative tumor burden. Mechanistically, VT104 potentiated TMZ-dependent {gamma}-H2AX genotoxic stress and RT+TMZ synergized with VT104 to abolish TEAD activity. Conclusion: Integrating YAP-TEAD inhibition with standard therapy introduces a clinically-relevant paradigm for synergistic treatment in recurrent GBM that both inhibits tumor infiltration and reduces therapeutic resistance to chemoradiation.

Cancer biology

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Thenzing Juda Silva Hurtado has the highest h-index among the authors (2).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (13)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.
TEAD Palmitoylation Inhibitors are Brain Penetrant and Enhance Survival in Preclinical Models of Recurrent Glioblastoma in Combination with Standard-of-Care Therapy - QAI OpenResearch